Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0V1QX
|
||||
Former ID |
DIB012118
|
||||
Drug Name |
Axogenesis Factor-1
|
||||
Synonyms |
Oncomodulin; CNS nerve growth factors, Alseres; CNS nerve growth factors, Boston Life Sciences; AF-1, Alseres; AF-1, Boston Life Sciences; Axogenesis Factor-1, Alseres; Axogenesis Factor-1, Boston Life Sciences
|
||||
Indication | Cerebrovascular ischaemia [ICD9: 434.91; ICD10:I61-I63] | Investigative | [543520] | ||
Company |
Children's Hospital Boston
|
||||
Target and Pathway | |||||
Target(s) | Tumor necrosis factor receptor superfamily member 16 | Target Info | Modulator | [543520] | |
Pathway Interaction Database | p75(NTR)-mediated signaling | ||||
Neurotrophic factor-mediated Trk receptor signaling | |||||
Reactome | Axonal growth inhibition (RHOA activation) | ||||
NRAGE signals death through JNK | |||||
p75NTR negatively regulates cell cycle via SC1 | |||||
Regulated proteolysis of p75NTR | |||||
NADE modulates death signalling | |||||
NRIF signals cell death from the nucleus | |||||
p75NTR recruits signalling complexes | |||||
NF-kB is activated and signals survival | |||||
Axonal growth stimulation | |||||
References |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.